Pacira BioSciences, Inc. Announces Net Product Sales for the Month and First Quarter of March 2022
April 12, 2022 at 08:00 am EDT
Share
Pacira BioSciences, Inc. announced net product sales for the month and first quarter of March 2022. For the month, the company EXPAREL net product sales were $129.2 million and $114.7 million for the first quarters of 2022 and 2021. iovera° net product sales were $3.0 million and $3.3 million for the first quarters of 2022 and 2021.
For the quarter, the company reported EXPAREL net product sales were $51.2 million and $44.3 million for the months March 2022 and 2021, respectively. iovera° net product sales were $1.1 million and $1.5 million for the months of March 2022 and 2021.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.